Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma-Reference-Cited by-同舟云学术

Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma

Published:2019-07-30 Issue:18 Volume:176 Page:3681-3694
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Halatsch Marc‐Eric¹,Kast Richard Eric²,Dwucet Annika¹,Hlavac Michal¹,Heiland Tim¹,Westhoff Mike‐Andrew³,Debatin Klaus‐Michael³,Wirtz Christian Rainer¹,Siegelin Markus David⁴,Karpel‐Massler Georg¹^ORCID

Affiliation:

1. Department of NeurosurgeryUlm University Medical Center Ulm Germany

2. IIAIGC Study Center Burlington VT USA

3. Department of Pediatrics and Adolescent MedicineUlm University Medical Center Ulm Germany

4. Department of Pathology and Cell BiologyColumbia University Medical Center New York NY USA

Funder

National Institute of Neurological Disorders and Stroke

Publisher

Wiley

Subject

Pharmacology

Link